Low-dose IL-2 therapy for immune-related adverse events via Tfh/Treg balance modulation: a prospective cohort and murine model study
Yifan Wang, Zhening Zhang, Yufei Li, Yongjing Cheng, Min Wang, Yudong Liu, Hao Li, Zhi Peng, Jing He · 2026
Read Low-dose IL-2 therapy for immune-related adverse events via Tfh/Treg balance modulation: a prospective cohort and murine model study by Yifan Wang, Zhening Zhang, Yufei Li, Yongjing Cheng, Min Wang, Yudong Liu, Hao Li, Zhi Peng, Jing He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13490026.txt.
Description
Wang and colleagues tested whether a low dose of interleukin-2, an immune messenger, can calm the autoimmune side effects that cancer immunotherapy sometimes triggers. The side effects arise when checkpoint drugs unleash immunity against healthy tissue, and current treatment blunts the cancer attack too. Their 2026 study profiled 26 gut-cancer patients before and after checkpoint therapy, then treated two mouse models with the low-dose regimen.
Patients who developed side effects showed helper T-cell activity genes surging early, outpacing the regulatory genes that normally restore balance. In mice, low-dose interleukin-2 restored that balance, reduced tissue inflammation, and lowered autoantibody production in the experiments described. Crucially, the treatment did not significantly weaken the checkpoint drugs' antitumor effect in the tumor-bearing model. Wang proposes the approach as a gentler alternative to broad immune suppression.
Catalog record
| CREATOR | Yifan Wang, Zhening Zhang, Yufei Li, Yongjing Cheng, Min Wang, Yudong Liu, Hao Li, Zhi Peng, Jing He |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |